What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
作者信息
Silvestris Nicola
机构信息
Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, 70124 Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", 70124 Bari, Italy.
出版信息
EBioMedicine. 2021 Dec;74:103733. doi: 10.1016/j.ebiom.2021.103733. Epub 2021 Dec 1.
Abstract
摘要
相似文献
1
What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?免疫功能低下患者对BNT162b2 mRNA疫苗的免疫反应是什么？
EBioMedicine. 2021 Dec;74:103733. doi: 10.1016/j.ebiom.2021.103733. Epub 2021 Dec 1.
2
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.接受间隔16周剂量的BNT162b2 mRNA疫苗接种的个体血浆对SARS-CoV-2奥密克戎刺突蛋白的识别
Cell Rep. 2022 Mar 1;38(9):110429. doi: 10.1016/j.celrep.2022.110429. Epub 2022 Feb 8.
3
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.BNT162b2 mRNA 疫苗接种后细胞和体液功能反应在 COVID-19 初治和恢复期患者中具有纵向差异。
Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21.
4
Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans.SARS-CoV-2 感染后或序贯接种 mRNA 疫苗对人体固有免疫反应的调节。
JCI Insight. 2024 May 8;9(9):e175401. doi: 10.1172/jci.insight.175401.
5
The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.接受检查点抑制剂治疗的癌症患者接种新冠病毒mRNA疫苗：我们已知与未知的情况
Immunotherapy. 2022 Feb;14(2):91-94. doi: 10.2217/imt-2021-0235. Epub 2021 Nov 8.
6
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
7
Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.血液透析患者中 BNT162b2 和 mRNA-1273 SARS-CoV-2 疫苗的真实世界有效性和免疫原性。
J Am Soc Nephrol. 2022 Jan;33(1):49-57. doi: 10.1681/ASN.2021060778. Epub 2021 Nov 17.
8
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.BNT162b2 mRNA 抗 SARS-CoV-2 疫苗接种健康和免疫功能低下个体的 NK 细胞频率、功能及其与疫苗结果的相关性。
Mol Med. 2022 Feb 8;28(1):20. doi: 10.1186/s10020-022-00443-2.
9
Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.年龄相关的对 BNT162b2 疫苗诱导的针对 SARS-CoV-2 阿尔法和贝塔变异株的中和作用的降低。
Microbiol Spectr. 2021 Dec 22;9(3):e0056121. doi: 10.1128/Spectrum.00561-21. Epub 2021 Dec 1.
10
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.SARS-CoV-2 mRNA 疫苗可在人体内引发强烈且持久的滤泡辅助性 T 细胞反应。
Cell. 2022 Feb 17;185(4):603-613.e15. doi: 10.1016/j.cell.2021.12.026. Epub 2021 Dec 23.
引用本文的文献
1
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.系统性硬化症成年患者对 BNT162b2 新冠病毒 mRNA 疫苗的抗体反应。
Clin Rheumatol. 2022 Sep;41(9):2755-2763. doi: 10.1007/s10067-022-06219-7. Epub 2022 May 26.
本文引用的文献
1
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.在一项前瞻性、开放性标签临床试验中，评估了 mRNA BNT162b2 疫苗在五组免疫功能低下患者和健康对照者中的安全性和有效性。
EBioMedicine. 2021 Dec;74:103705. doi: 10.1016/j.ebiom.2021.103705. Epub 2021 Nov 30.
2
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.成年人实体瘤中接受两剂和三剂 BNT162b2 mRNA 疫苗的免疫反应。
Nat Med. 2021 Nov;27(11):2002-2011. doi: 10.1038/s41591-021-01542-z. Epub 2021 Sep 30.
3
Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults.非免疫功能低下的成年人接种两剂 BNT162b2 后 3 个月抗体滴度下降。
Clin Microbiol Infect. 2022 Jan;28(1):139.e1-139.e4. doi: 10.1016/j.cmi.2021.08.023. Epub 2021 Sep 9.
4
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial.脆弱患者的 COVID-19 疫苗接种：当前证据和跨疾病的协调试验。
Front Immunol. 2021 Aug 10;12:704110. doi: 10.3389/fimmu.2021.704110. eCollection 2021.
5
Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.心脏和胸部移植受者对两剂 SARS-CoV-2 信使 RNA 疫苗 BNT162b2 的体液和 T 细胞应答较差。
Clin Res Cardiol. 2021 Aug;110(8):1142-1149. doi: 10.1007/s00392-021-01880-5. Epub 2021 Jul 9.
6
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.BNT162b2 疫苗在心脏移植受者中的应用：临床经验和抗体反应。
J Heart Lung Transplant. 2021 Aug;40(8):759-762. doi: 10.1016/j.healun.2021.04.003. Epub 2021 Apr 21.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
8
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.COVID-19 中的细胞因子风暴：发病机制和治疗中使用的抗炎药物概述。
Clin Rheumatol. 2020 Jul;39(7):2085-2094. doi: 10.1007/s10067-020-05190-5. Epub 2020 May 30.
Zotero 插件